A team of physicians at the German Center for Immunotherapy at Erlangen University Hospital has succeeded for the first time worldwide in treating a 21-year-old female patient with therapy-resistant, severe chronic inflammatory bowel disease (ulcerative colitis) using cell therapy with CD19 CAR-T cells. 

The 21-year-old patient had been suffering from highly active Colitis ulcerosa for five years and was no longer responding to any of the available medications, including various targeted biologics and JAK inhibitors.  

After CAR-T cell therapy, the diarrhoea and abdominal pain disappeared completely, colonoscopies showed complete healing of the previously inflamed intestinal mucosa, and body weight rose to a healthy normal level within a few months. For the first time in years, the patient is able to live a normal life again. 

For this cell-based immunotherapy, the patient’s own immune cells (T lymphocytes) are taken from the blood and genetically modified to recognise the surface molecule CD19.  

CD19 is characteristic of B lymphocytes, which are malfunctioning in many autoimmune diseases. This technology was originally developed for patients with malignant B-cell diseases (lymph node cancer). Studies have now shown that CAR-T cells can also be effective in certain autoimmune diseases. 

The particular advantage is that the modified CAR-T cells penetrate deep into the affected tissue and permanently switch off the “diseased” autoreactive B cells. The diseased B cells are then replaced by healthy, functional cells. 

“The results are very promising and give cause for great hope for those affected,” said Professor Dr Fabian Müller, head of the CAR-T Cell Unit at Medical Clinic 5. 

Treatment with CAR-T cells at the German Center for Immunotherapy was carried out through interdisciplinary collaboration between various departments of Medical Clinic 1 at Erlangen University Hospital.

Diana Turner, Deputy Editor, DDW